Question 1

How many shares of CPRX does UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC own?

Accepted Answer

As of 2026-Q2, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds 284,154 shares of CPRX (CATALYST PHARMACEUTICALS INC).

Question 2

What is UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's CPRX position worth?

Accepted Answer

As of 2026-Q2, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's CPRX position is worth $8.9M.

Question 3

Is UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC buying or selling CPRX?

Accepted Answer

In 2026-Q2, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased their CPRX position (+1.2% change in shares).

Question 4

When did UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC first buy CPRX?

Accepted Answer

Based on available 13F filings, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC first reported a position in CPRX in 2024-Q3. They have held the position across 29 quarters.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Increased	284,154	+1.2%	$8.9M	0.0%	$31.43	28
2026-Q1	Increased	280,889	+0.6%	$7M	0.0%	$23.92	27
2025-Q4	Increased	279,281	+0.7%	$6.5M	0.0%	$23.29	27
2025-Q3	Decreased	277,301	-52.6%	$5.5M	0.0%	$19.55	0
2025-Q2	Increased	585,671	+11.3%	$12.7M	0.0%	$21.78	31
2025-Q1	Increased	526,297	+99.4%	$12.8M	0.0%	$24.69	45
2024-Q4	Increased	263,905	+11.7%	$5.5M	0.0%	$21.07	30
2024-Q3	Decreased	236,222	-5.9%	$4.7M	0.0%	$19.56	0